Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $18.75.
A number of brokerages recently weighed in on UNCY. Weiss Ratings raised shares of Unicycive Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, June 9th. Zacks Research upgraded Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. HC Wainwright decreased their target price on Unicycive Therapeutics from $22.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, June 30th. B. Riley Financial reiterated a "buy" rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded Unicycive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 15th.
Check Out Our Latest Report on Unicycive Therapeutics
Unicycive Therapeutics Price Performance
Shares of NASDAQ:UNCY opened at $5.16 on Monday. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $8.74. The business has a 50-day moving average of $5.34 and a two-hundred day moving average of $6.52. The firm has a market capitalization of $143.71 million, a PE ratio of -2.95 and a beta of 1.79.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.41. As a group, research analysts anticipate that Unicycive Therapeutics will post -1.17 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. State Street Corp lifted its stake in shares of Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company's stock worth $376,000 after acquiring an additional 10,400 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. increased its holdings in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Unicycive Therapeutics in the 1st quarter valued at approximately $161,000. Finally, Bank of America Corp DE raised its position in shares of Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock valued at $194,000 after purchasing an additional 29,378 shares in the last quarter. 40.42% of the stock is owned by institutional investors and hedge funds.
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
